AML drug venetoclax under Real-World watch in south korea
NCT ID NCT04826523
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how safe and effective the oral drug venetoclax (Venclexta) is for adults with acute myeloid leukemia (AML) when used in everyday medical practice. About 150 people in South Korea took the drug as prescribed by their doctor for up to 7 months. Researchers tracked side effects and how well the cancer responded to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (Venclexta) tablets
What this could lead to
If successful, this study will confirm that venetoclax is a safe and effective treatment option for AML in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like serious infections or low blood counts are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chonnam National University Hwasun Hospital /ID# 257478
Hwasun-gun, Jeonranamdo, 58128, South Korea
-
Gachon University Gil Medical Center /ID# 239008
Incheon, Gyeonggido, 21565, South Korea
-
Korea University Anam Hospital /ID# 231022
Seoul, Seoul Teugbyeolsi, 02841, South Korea
-
Kosin University Gospel Hospital /ID# 257399
Busan, Busan Gwang Yeogsi, 49267, South Korea
-
Kyungpook National University Hospital /ID# 257398
Daegu, Daegu Gwang Yeogsi, 41944, South Korea
-
Pusan National University Hospital /ID# 239010
Busan, Busan Gwang Yeogsi, 49241, South Korea
-
Samsung Medical Center /ID# 239009
Seoul, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Hospital /ID# 257477
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Yeungnam University Medical Center /ID# 239007
Daegu, 42415, South Korea
-
Yonsei University Health System Severance Hospital /ID# 239006
Seoul, 03722, South Korea